FDA approves Fasenra for severe eosinophilic asthma
The FDA has approved Fasenra for the add-on maintenance treatment of patients with severe asthma aged 12 years and older...
List view / Grid view
The FDA has approved Fasenra for the add-on maintenance treatment of patients with severe asthma aged 12 years and older...
The Asia-Pacific (APAC) asthma therapeutics market is expected to grow significantly from $4.1 billion in 2016 to around $6 billion by 2023...